Comparing two myeloma treatments for new patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug combination (HLX15-SC) against an approved treatment (DARZALEX FASPRO) along with lenalidomide and dexamethasone for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Newly diagnosed with multiple myeloma and not eligible for a stem cell transplant
- Good overall health (ECOG score 0 or 1)
- Adequate blood counts and kidney/liver function
- Willing to use effective birth control
- No prior cancer treatment for myeloma except a short course of steroids
- No serious heart, lung, or other medical conditions
- No active hepatitis B, C, or HIV infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different combinations of medicines in people who still have signs of multiple myeloma after a stem cell transplant. One group gets teclistamab and talquetamab, and the other gets daratumumab and lenalidomide. The goal is to see which works better at removing any remaining cancer cells.
This study tests a new medicine (HLX15-IV) compared to the standard treatment DARZALEX, both given with lenalidomide and dexamethasone (Rd). It is for people newly diagnosed with multiple myeloma who are not able to have a stem cell transplant.
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
This trial tests whether a new drug called elranatamab combined with lenalidomide works better than the standard daratumumab/lenalidomide combination as maintenance therapy after a stem cell transplant for newly diagnosed myeloma.
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
This trial tests if adding the immunotherapy drug elranatamab (with or without lenalidomide) after initial treatment works better than the usual care for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.